Home > Investor Relations > Financial Results > Revenues by Product

Revenues by Product

(Billions of Yen)
  2012 2013 2014
Sales 375.2 401.3 436.9
  Excl.Tamiflu® 363.2 390.2 423.8
  Domestic 320.9 329.2 349.5
  Oncology 156.1 172.4 188.9
  Avastin® 65.5 75.4 82.3
Herceptin® 28.7 30.9 31.2
Rituxan® 24.7 26.2 26.2
Tarceva® 9.5 10.4 11.5
Xeloda® 10.9 11.3 10.4
Neutrogin® 8.8 8.1 5.9
Perjeta®* - 2.4 9.1
Kadcyla®* - - 4.0
Alecensa®* - - 1.4
Other products 8.2 7.6 6.9
Bone and joint diseases 66.3 60.6 69.6
  Actemra® 17.1 20.4 24.1
Edirol® 7.9 15.0 19.2
Suvenyl® 12.3 11.9 10.7
Alfarol® 8.1 6.4 4.9
Bonviva®* - 0.5 3.4
Other products 20.8 6.3 7.4
Renal diseases 48.1 48.9 44.7
  Mircera® 17.8 22.5 22.6
Oxarol® 12.3 12.2 12.2
Epogin® 14.5 10.5 6.6
Other products 3.6 3.7 3.4
Transplant, Immunology, and Infectious diseases 20.3 18.8 20.8
  CellCept® 6.5 7.2 6.5
Pegasys® 6.9 5.5 7.0
Copegus® 2.0 1.3 3.1
Other products 4.9 4.8 4.2
Others 30.1 28.6 25.6
  Sigmart® 9.5 8.6 6.4
Other products 20.5 20.0 19.2
Overseas 42.3 61.1 74.3
    Actemra® 25.6 43.2 55.7
To Roche 25.6 42.9 55.1
Neutrogin® 13.9 14.7 15.7
Other products 2.8 3.1 2.9
Tamiflu® 12.0 11.0 13.0
  Ordinary use 10.2 10.1 12.9
Govt. stockpiles etc. 1.9 0.9 0.2
Royalties and other operating income 11.3 22.4 24.2
Revenues (total) 386.6 423.7 461.1
    Domestic 338.0 350.8 372.9
Overseas 48.6 72.9 88.2

*Perjeta (launched in September 2013), Kadcyla (launched in April 2014), Alecensa (launched in September 2014), Bonviva (launched in August 2013)

Sales by Strategic Field (FY2014)

Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.